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lopidogrel is the most widely used P2Y 12 receptor inhibitor and is the only agent of this class currently approved for use in patients with stable coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). 1, 2 Although the efficacy of dual antiplatelet therapy with aspirin and clopidogrel has been consistently shown in different clinical settings, rates of ischemic recurrences remain elevated despite this treatment regimen, especially in high-risk patients. 2 This is in part attributed to the broad interindividual variability in responses to clopidogrel, 2 which leads to ≈30% of patients experiencing high on-treatment platelet reactivity while receiving clopidogrel. 2 It is important to note that high ontreatment platelet reactivity status has been strongly associated with an increased risk of ischemic events, in particular, stent thrombosis, following PCI. 2 This underscores the need for strategies aimed to enhance platelet inhibition in high-risk patients treated with PCI.
Multiple approaches have been advocated to reduce high on-treatment platelet reactivity rates. Intuitively, the use of the more potent P2Y 12 receptor inhibitors represents an ideal treatment option. 3 Ticagrelor is an oral, reversibly binding, noncompetitive P2Y 12 receptor inhibitor with rapid onset and offset of action and provides a stronger and more consistent platelet inhibition than clopidogrel. 3 In turn, in the PLATO trial (Study of Platelet Inhibition and Patient Outcomes), ticagrelor, at the standard dose of 180 mg loading dose (LD) followed by a 90 mg BID maintenance dose, was associated with a significant reduction in long-term ischemic events, in comparison with clopidogrel, in patients with acute coronary syndrome. Although this was also associated with an increase in bleeding events, the net benefit and all-cause death favored ticagrelor. 4 In the PEGASUS trial (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54), conducted in patients who experienced a prior (1-3 years) myocardial infarction, adjunctive ticagrelor therapy, tested at 2 different doses (90 mg BID and 60 mg BID) significantly reduced ischemic recurrences on top of aspirin, albeit at the expense of increased bleeding complications. It is notable that, in this trial, low-dose ticagrelor (60 mg BID) seemed to have a better safety/efficacy profile, by means of similar ischemic protection, but numerically lower bleeding events and dyspnea, in comparison with the standard dose (90 mg BID). 5 Moreover, in a pharmacodynamic post hoc analysis, both dosing regimens seemed to provide similar levels of platelet inhibition. 6 Therefore, the use of low-dose ticagrelor seems an appealing strategy to optimize ischemic and hemorrhagic risk in elevated-risk patients with stable CAD undergoing PCI. However, to date, there are still limited pharmacodynamic and pharmacokinetic data on the ticagrelor 60 mg BID dos-ing regimen. In addition, part of the clinical benefit (eg, improved mortality), and the side effects (eg, dyspnea), as well, of ticagrelor are thought to be mediated by off-target (non-P2Y 12 -related) effects, in particular, by an increase in adenosine plasma levels via the inhibition of the equilibrative nucleoside transporter 1 and cellular adenosine reuptake. 7 However, the effects of low-dose ticagrelor on adenosine metabolism have been poorly explored.
In (2 hours post-ticagrelor LD, at least 4 hours after clopidogrel LD or at least 5 days of clopidogrel 75-mg maintenance therapy) and after 30 days of maintenance dose treatment. At this time point, both trough and peak levels of platelet reactivity were measured. Samples for measurements of adenosine reuptake (primary end point) and plasma adenosine levels were collected at the time of PCI and at 30 days. High-sensitivity troponin was also measured in serum samples before PCI and the morning after PCI, as a surrogate marker to explore the effects of ticagrelor and clopidogrel on myocardial injury. The study found no impact of ticagrelor, in comparison with clopidogrel, on in vitro adenosine uptake and adenosine plasma levels, both with the LD and with the 90-mg and 60-mg maintenance dose regimens. Ticagrelor LD achieved greater antiplatelet effect than clopidogrel at the time of PCI, and both maintenance dose regimens of ticagrelor led to significantly lower platelet reactivity than clopidogrel, with nearly no high on-treatment platelet reactivity. It is notable that ticagrelor 90 mg seemed to provide a slightly more potent effect than ticagrelor 60 mg, but it was associated with a higher incidence of dyspnea. Pharmacokinetic levels for ticagrelor tracked pharmacodynamic data, and results were consistent regardless of CYP2C19 genetic status. Ischemic and bleeding events were very low and similar between groups, and there was no difference between ticagrelor and clopidogrel on PCI-induced increase in high-sensitivity troponin. 8 The authors need to be congratulated for their elegant study, because they explored for the first time the pharmacodynamic effects of different ticagrelordosing regimens in patients with stable CAD undergoing PCI, and the impact of low-dose ticagrelor on adenosine levels, as well. The major strength of the study is that it enrolled a fairly high number of patients and was conducted with sound methodology, including multiple platelet function testing, pharmacokinetic analysis, comprehensive assessment of adenosine reuptake, markers of myocardial injury, and genetic testing. Showing that ticagrelor 60 mg provides more potent and consistent antiplatelet effects than clopidogrel, this mechanistic study can be potentially clinically relevant. In fact, because of the better tolerability and safety profile, low-dose ticagrelor could be considered as either an alternative to clopidogrel for high-risk patients with stable CAD undergoing PCI or an alternative to standard-dose ticagrelor for the maintenance treatment of low-risk patients with acute coronary syndrome.
The study, however, should also be interpreted in light of some potential limitations. The findings that ticagrelor did not impact adenosine reuptake are consistent with recent investigations showing no improvement in endothelial function measured by pulse amplitude tonometry, or increase in systemic adenosine plasma levels in patients receiving standard-dose ticagrelor, in comparison with thienopyridines. 9 However, this is in contrast with other prior studies showing a ticagrelorinduced increase in adenosine plasma concentration at therapeutic doses, 7 and with animal models showing that ticagrelor is able to exert cardioprotective effects by reducing necrotic injury and edema formation following a myocardial infarction via adenosine-dependent mechanisms. 10 Therefore, although it is still likely an effect of ticagrelor on adenosine in vivo at the tissue level, the correct methodology to assess this issue remains not well established. In addition, the present study was conducted in a stable setting, whereas ticagrelor effects on adenosine were mostly shown in post-acute coronary syndrome settings, which may have an impact on study findings. The study was not powered to assess clinical outcomes; therefore, no safety or efficacy conclusion on low-dose ticagrelor post-PCI can be drawn. This study showed slightly higher platelet inhibition with ticagrelor 90 mg in comparison with ticagrelor 60 mg, which is in contrast with findings from the pharmacodynamic post hoc analysis of PEGASUS. 6 However, both these studies were not powered to detect pharmacodynamic differences between different ticagrelordosing regimens, and findings should be considered as hypothesis generating. Finally, the study enrolled a very low-risk population, as confirmed by the near absence of ischemic or bleeding events. This could explain the lack of effect of potent platelet inhibition by ticagrelor on markers of myocardial injury, which are most likely to be detected in higher-risk patients. Indeed, despite the enhanced pharmacodynamic effects in comparison with clopidogrel, such a low-risk population is unlikely to receive any clinical benefit by this strategy. Howev-er, the use of a low-dose ticagrelor maintenance regimen seems an attractive strategy to optimize ischemic protection and bleeding risk in high-risk patients with stable CAD, such as those with diabetes mellitus who are known to have an impaired response to clopidogrel. 11 This strategy is currently being tested in different studies, including the THEMIS trial (A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients with Type 2 Diabetes Mellitus) (NCT01991795), investigating whether the adjunctive use of ticagrelor 60 mg BID can further reduce major cardiovascular events in patients with diabetes mellitus, and the OPTIMUS IV study (Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI; ClinicalTrials.gov. Unique identifier: NCT03437044), exploring the pharmacodynamic profiles of low-dose ticagrelor in patients with diabetes mellitus who have stable CAD undergoing PCI.
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